المؤلفون: T. Ciuleanu, V. Sailer, T. Herrmann, Mark M. Zalupski, J. Chick, J. Trojan, M. Diculescu, Philip A. Philip, K. Brock, N. M. Hoepffner, D. Albert, A. Roth

المصدر: Investigational New Drugs, Vol. 25, No 4 (2007) pp. 385-90

مصطلحات موضوعية: Male, medicine.medical_specialty, Quinazolines/therapeutic use, medicine.medical_treatment, Leucovorin, Phases of clinical research, Antineoplastic Agents, Adenocarcinoma, Isoindoles, Thymidylate Synthase/antagonists & inhibitors, Gastroenterology, Metastatic carcinoma, Glutarates, Thymidylate synthase inhibitor, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Pharmacology (medical), Clinical significance, ddc:616, Pharmacology, Chemotherapy, biology, business.industry, Antineoplastic Agents/therapeutic use, Thymidylate Synthase, Middle Aged, Survival Analysis, Fluorouracil/administration & dosage, Biliary Tract Neoplasms, Treatment Outcome, Glutarates/therapeutic use, Oncology, Biliary tract, Fluorouracil, Leucovorin/administration & dosage, Quinazolines, biology.protein, Biliary Tract Neoplasms/drug therapy/pathology, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adenocarcinoma/drug therapy/secondary, Bolus (digestion), business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e3d3a015daf4890cc88297aa384433
https://doi.org/10.1007/s10637-007-9040-0